Table 2 Nuclease detection methods

FEN1

Cancer Profiling Array I

[24]

IHC

[24, 25]

semiquantitative reverse transcription-PCR

[25]

APE1

IHC

[26,27,28,29, 33, 39]

radioactivity-based or fluorescence- based nuclease activity assay

[20]

ELISA

[30, 34, 36]

liquid chromatography and tandem mass spectrometry with isotope dilution

[31]

genotyping assays and in silico prediction

[32]

RT-qPCR

[35]

qPCR

[37]

PCR

[38]

RFLP

[38]

whole genome gene expression of melanoma tumors, using Illumina DASL approach

[40]

XPF/XPG

IHC

[21, 42, 44]

RT-qPCR

[45]

MRN Complex

IHC

[47,48,49,50]

PCR

[48, 49, 51]

TREX2

knock out mouse model, IHC, ssDNA and dsDNA degradation assays

[52]

SND1

IHC

[53, 56]

chicken chorioallantoic membrane assay, human umbilical vein endothelial cell differentiation assay

[54]

RT-qPCR

[57]

DNaseI

phenotyping conducted on urine samples from participants, using electrophoresis in thin polyacrylamide gel followed by immunoblotting with an antihuman DNaseI antibody

[58, 59]

RNaseL

gene sequencing, 5′ nuclease TaqMan® allelic discrimination assay, genotyping using PCR and WAVE DHPLC

[60, 61]

enzymatic assay using rRNA as a substrate

[62]

analysis of tumor DNA and genotyping of somatic tissues of patients

[63]

RNaseI

WB, ELISA, and immunoprecipitation

[64, 65]

Serum RNase activity

serum RNase enzymatic activity was assayed using two substrates: t-RNA (T) from E. coli MRE 600 and the synthetic polycytidylic acid (poly-C). Elevated serum ribonuclease activity (SRA) was expressed in terms of the amount of bovine serum RNaseA from bovine pancreas in ngeq/ml that yields the same extinction Coeff. at the 260 nm wavelength.

[66]